National and Kapodistrian University of Athens
Προσδιορισμός του δείκτη κόστους αποτελεσματικότητας κατά τη διαχείριση ασθενών με καρκίνο του πνεύμονα στην Ελλάδα: ένα νέο θεωρητικό υπόδειγμα οικονομικής αξιολόγησης και οι πρακτικές του εφαρμογές για την δημόσια υγεία
Abstract
dc:descriptionIntroduction: Economic evaluation compares the costs and health effects of an intervention in order to maximize health benefits from available resources. Aim: The scope of this doctoral thesis was twofold. The primary scope was to develop a new methodological model of cost-effectiveness analysis for lung cancer patients in Greece. The second aim was to estimate the cost-effectiveness ratio for competitive interventions based on a real data set. Hence, an economic evaluation was also conducted alongside a prospective, multicenter, randomized, trial, to evaluate pemetrexed relative to erlotinib in pre-treated patients with metastatic non small cell lung cancer (NSCLC) in Greece. Methods: We developed a new model which combines the cost-effectiveness and budget impact analysis in a unique model. The proposed model relaxed the simplified constant-return-on-scale assumption of willingness to pay (λ) for innovative interventions introducing a log-sigmoid function derived from Weibull family. In our model, it was assumed that the budget is exogenous and has been set by the budget holders in a small disease-specific area. Moreover, in an attempt to practically describe the real world, the proposed model allows a flexible -upper bounded- budget. Frequently, budget allocation amongst therapeutic areas lies on historical, political and social criteria and thus, the application of prominent instruments such as mathematical programming seems difficult to be practically implemented for the optimum allocation of the health care budgets. In our case, a far less ambiguous approach was adopted to estimate the local equilibrium which is driven by the de facto budget availability in a disease specific context. Results: The model allows the determination of λ to be different across different therapeutic areas, taking into account the differences in the “production” of a QALY amongst patient groups. The model demonstrates how willingness to pay changes, as we hold the budget fixed and allows the incremental effectiveness to vary, how the budget must be expanded to afford an innovative technology given a specific willingness to pay path -fixed or not-, or a combination of the above. Concerning the second part, statistical analysis showed that pemetrexed and erlotinib had comparable effectiveness and thus a cost minimization analysis was conducted to assess and find the least costly option. Patient-level resource utilization data were combined with unit cost data and they were then aggregated to compute total treatment cost for each patient. Conclusion: The model which developed is in accordance with the principles of microeconomic theory and can be used to estimate the equilibrium in the context of lung cancer patients. Concerning the second part, the evidence did not support any survival or cost difference between pemetrexed and erlotinib, and thus, they can be deemed equivalent, except if any other relevant parameter such as quality of life makes a difference.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Fragoulakis, Vasileios
- Φραγκουλάκης, Βασίλειος
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/28691